用于接受生育治疗的妇女的血管扩张剂
Rosa B Gutarra-Vilchez1, Juan C Vazquez2, Demián Glujovsky3
1Facultad de Medicina Humana, Universidad de San Martin de Porres. Clínica Internacional Sede La Molina, Lima, Peru.
The Cochrane database of systematic reviews
|March 6, 2025
概括
血管扩张剂可能会略微增加临床怀孕率,但也会增加生育治疗中副作用的风险. 与安慰剂相比,活产率几乎没有差异,对子宫内膜厚度的影响不确定.
科学领域:
- 生殖医学 生殖医学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 辅助生殖技术 (ART) 的成功率已经停滞不前.
- 血管扩张剂正在研究改善子宫内膜接受度和妊娠子宫状况的潜在益处.
- 本综述评估了血管扩展剂在生育治疗中的有效性和安全性.
研究的目的:
- 评估血管扩张剂在改善接受生育治疗的妇女怀孕后果方面的有效性.
- 评估血管扩展剂的安全性,包括潜在的副作用.
- 为了比较血管扩张剂与安慰剂,没有治疗或其他药物,如雌激素.
主要方法:
- 45项随机对照试验 (RCT) 的系统审查和元分析,涉及4404名女性.
- 搜索了多个数据库和试验注册表,直到2024年4月.
- 提取有关活产,临床怀孕,副作用和子宫内膜厚度的数据;使用GRADE评估证据确定性.
主要成果:
- 与安慰剂 (低确定性证据) 相比,血管扩张剂在活产率上几乎没有差异.
- 使用血管扩展剂与安慰剂 (中度确定性证据) 相比,临床怀孕率可能会增加.
- 与安慰剂相比,血管扩张剂可能会增加整体副作用 (中度确定性证据),对子宫内膜厚度的影响不确定.
结论:
- 与安慰剂或雌激素相比,血管扩张剂在生育治疗中对活产率的好处很小,甚至没有.
- 与安慰剂相比,血管扩展剂可能增加临床怀孕率和观察到的副作用.
- 在将血管扩展剂与雌激素进行比较时,对子宫内膜厚度和具体结果的证据仍然不确定;需要进一步进行高质量的试验.
相关概念视频
Antihypertensive Drugs: Vasodilators
455
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
455
Infertility in Females
255
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
Endometriosis, a condition characterized by abnormal growth of...
255
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
124
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
124
Adrenergic Antagonists: ɑ and β-Receptor Blockers
399
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
399
Heart Failure Drugs: β-Blockers
303
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
303
Antianginal Drugs: Nitrates and β-Blockers
486
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
486


